The current standard-of-care for BRAF mutant melanoma is a combination of BRAF and MEK inhibitors, and this combination with the addition of a CDK4/6 inhibitor induces sustained tumour regression in both BRAF and NRAS mutant melanoma preclinical models [10,11,36,37,38]. Here, MAP2K7 is linked to melanoma.